Zacks Investment Research upgraded shares of Forward Pharma A/S (NASDAQ:FWP) from a hold rating to a buy rating in a research report sent to investors on Wednesday. They currently have $22.00 target price on the stock.
According to Zacks, “Forward Pharma A/S is a biotechnology company. It is focused on the immunomodulatory compound dimethyl fumarate and derivatives, for applications as a pharmaceutical drug product to treat immune disorders such as multiple sclerosis and psoriasis. The Company is advancing its lead drug candidate FP187 for possible treatment of immune disorders including multiple sclerosis and psoriasis. Forward Pharma A/S is headquartered in Copenhagen, Denmark. “
Other equities analysts have also issued reports about the company. Leerink Swann set a $28.00 price target on Forward Pharma A/S and gave the company a buy rating in a research note on Monday, April 3rd. Jefferies Group LLC restated a hold rating and set a $41.00 price target on shares of Forward Pharma A/S in a research note on Friday, March 31st. Finally, JMP Securities lowered Forward Pharma A/S from an outperform rating to a market perform rating in a research note on Monday, April 3rd.
Shares of Forward Pharma A/S (NASDAQ:FWP) traded up 3.11% during mid-day trading on Wednesday, reaching $19.59. The company’s stock had a trading volume of 10,570 shares. The firm’s market capitalization is $922.71 million. Forward Pharma A/S has a 12 month low of $14.89 and a 12 month high of $33.00. The company has a 50 day moving average of $28.44 and a 200-day moving average of $22.36.
ILLEGAL ACTIVITY NOTICE: This report was first posted by sleekmoney and is the property of of sleekmoney. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at http://sleekmoney.com/forward-pharma-as-fwp-lifted-to-buy-at-zacks-investment-research/1733368.html.
A number of institutional investors have recently modified their holdings of FWP. Motley Fool Wealth Management LLC raised its position in shares of Forward Pharma A/S by 4.1% in the fourth quarter. Motley Fool Wealth Management LLC now owns 72,339 shares of the company’s stock valued at $1,085,000 after buying an additional 2,844 shares in the last quarter. Sandia Holdings LLC purchased a new position in shares of Forward Pharma A/S during the fourth quarter valued at about $1,651,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Forward Pharma A/S during the fourth quarter valued at about $5,918,000.
About Forward Pharma A/S
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/forward-pharma-as-fwp-lifted-to-buy-at-zacks-investment-research/1733368.html
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.